Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

Abstract Background Neoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast cancer. Although the dual-targeted therapy has significantly improved the pathological complete response (pCR) rate, further investigation is n...

Full description

Bibliographic Details
Main Authors: Zheng-Jun Yang, Fei Xin, Zu-Jin Chen, Yue Yu, Xin Wang, Xu-Chen Cao
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
HER2 positive
Breast cancer
Neoadjuvant chemotherapy
Dual-targeted therapy
Online Access:https://doi.org/10.1186/s12885-024-11871-0

Similar Items

Similar Items